Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy.

ABSTRACT: The present study evaluated the impact of prior radiotherapy (RT) on patients with advanced non-small cell lung cancer (NSCLC) receiving therapy with immune checkpoint inhibitors (ICIs) and further assessed the prognostic factors in patients receiving both RT and ICI. Patients diagnosed with NSCLC at the Catholic Medical Center and Asan Medical Center between January 2016 and October 2020 and who received immunotherapy were retrospectively reviewed. Among 240 patients, poor Eastern Cooperative Oncology Group (ECOG) score, high PD-L1 expression, and ICI-related adverse events (AE) were significantly associated with progression-free survival (PFS) (HR, 2.654; 95% CI, 1.484-4.749; p = 0.001; HR, 0.645; 95% CI, 0.449-0.926, p = 0.017; HR, 0.430; 95% CI, 0.229-0.808; p = 0.009, respectively). A

SUBMITTER: Lim JU 

PROVIDER: S-EPMC8397093 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature